237 related articles for article (PubMed ID: 10620545)
1. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
Stigant CE; Cohen J; Vivera M; Zaltzman JS
Am J Kidney Dis; 2000 Jan; 35(1):58-63. PubMed ID: 10620545
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors after renal transplantation.
Bravo P; Felgueiras J; Santos C; Oliveira C; Ponce P
Transplant Proc; 2008 Apr; 40(3):740-2. PubMed ID: 18455003
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
Formica RN; Friedman AL; Lorber MI; Bia MJ
Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
[TBL] [Abstract][Full Text] [Related]
6. Is it time for ACE inhibitors in chronic allograft nephropathy?
Lewis JB; Helderman JH
Am J Kidney Dis; 2000 Jan; 35(1):154-6. PubMed ID: 10620559
[No Abstract] [Full Text] [Related]
7. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation.
Orlić L; Mikolasević I; Sladoje-Martinović B; Bubić I; Pavletić-Persić M; Racki S
Coll Antropol; 2013 Sep; 37(3):809-14. PubMed ID: 24308221
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E
Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
[TBL] [Abstract][Full Text] [Related]
9. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.
Zaltzman JS; Nash M; Chiu R; Prasad R
Nephrol Dial Transplant; 2004 Apr; 19(4):940-4. PubMed ID: 15031353
[TBL] [Abstract][Full Text] [Related]
10. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients.
Bunke M; Ganzel B
J Heart Lung Transplant; 1992; 11(6):1194-9. PubMed ID: 1457446
[TBL] [Abstract][Full Text] [Related]
11. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
12. [A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension].
Ye RJ; He QY; Gai J; Shang Y
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Sep; 27(9):581-4. PubMed ID: 15498266
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
[TBL] [Abstract][Full Text] [Related]
14. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
15. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration.
Montanaro D; Gropuzzo M; Tulissi P; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
Transplant Proc; 2004 Apr; 36(3):692-4. PubMed ID: 15110633
[TBL] [Abstract][Full Text] [Related]
16. [Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
Kutyrina IM; Tareeva IE; Nosikov VV; Kamyshova ES; Gorashko NM; Chistiakov DA; Okonova EB; Troepol'skaia OV
Ter Arkh; 1999; 71(6):30-4. PubMed ID: 10420452
[TBL] [Abstract][Full Text] [Related]
17. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study.
Kessler M; Hestin D; Mayeux D; Mertes PM; Renoult E
Clin Nephrol; 1996 Feb; 45(2):83-9. PubMed ID: 8846535
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
19. [Clinical effects of trandolapril in chronic glomerulonephritis patients with renal insufficiency].
Yoshida A; Takeda A; Fukuda M; Toda S; Morozumi K
Nihon Jinzo Gakkai Shi; 2000 May; 42(4):333-7. PubMed ID: 10897592
[TBL] [Abstract][Full Text] [Related]
20. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
